The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Cartesian Therapeutics Inc (RNAC) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 1.87%, to $1.09. The Cartesian Therapeutics Inc has recorded 27,962 volume in the after hours trading session.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Cartesian Therapeutics Inc is $166.06M. A total of 1.98 million shares were traded on the day, compared to an average of 664.11K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, RNAC has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 3,637 shares. Over the last 12 months, there were 5 BUYs and 23 SELLs from insiders. Insiders purchased 693,738 shares during that period but sold 219,441.
In the most recent transaction, Brunn Carsten sold 2,932 shares of RNAC for 1.06 per share on Sep 25. After the transaction, the President and CEO now owns 783,081 company shares. In a previous transaction on Sep 25, TRABER PETER G sold 705 shares at 1.06 per share. RNAC shares that Chief Medical Officer owns now total 451,826.
Among the insiders who sold shares, Brunn Carsten disposed of 13,473 shares on Jan 05 at a per-share price of $1.13. This resulted in the President and CEO holding 786,013 shares of RNAC after the transaction. In another insider transaction, TRABER PETER G sold 3,465 shares at $1.13 per share on Jan 05. Company shares held by the Chief Medical Officer now total 446,121.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for RNAC in the last 3 months, the mean price target is $3.25 with high estimates of $5.00 and low estimates of $1.00. In terms of 52-week highs and lows, RNAC has a high of $1.99 and a low of $0.79.
As of this writing, RNAC has an earnings estimate of -$0.07 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.02 per share and a lower estimate of -$0.12. The company reported an EPS of -$0.07 in the last quarter, which was 12.50% higher than expectations of -$0.08.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RNAC’s latest balance sheet shows that the firm has $128.06M in Cash & Short Term Investments as of fiscal 2021. There were $35.28M in debt and $72.25M in liabilities at the time. Its Book Value Per Share was $0.39, while its Total Shareholder’s Equity was $22.52M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNAC is Buy with a score of 4.40.